Expect Miracles Foundation is proud to announce the appointment of five new members to its Board of Directors in 2022. The Foundation is incredibly excited to continue to expand and welcome new leadership—all in support of the cancer community.
The Board of Directors has appointed Amy Fisher, Clint Harris, Jane Mancini, Andy McFetridge, and Sherry Moreland as Directors. Amy Fisher is the Managing Director of Strategic Relationships for Touchstone Investments. Clint Harris is the Head of Wealth Management Platforms for Invesco US Wealth Management Intermediaries. Jane Mancini is the Global Head of Business Development for BNY Mellon’s Asset Servicing business. Andy McFetridge is the Head of Strategic Relationships and Investment Specialists at John Hancock Investment Management. Sherry Moreland is the President and Chief Operating Officer at Mediant.
Dedicated to progress and committed to care, Expect Miracles Foundation rallies the financial services industry and beyond to invest in life-saving cancer research while advancing the economic and emotional health of people impacted by cancer. The Foundation’s donor and support base include the top financial firms and industry leaders.
“We are incredibly eager to have Amy, Jane, Sherry, Andy, and Clint join the Board. Their dedication to our mission, to create hope for those who need it most, will certainly make 2022 an impactful year. We look forward to their contributions and to a future of progress and care for the cancer community,” said Frank Strauss, Founder and Chairman of Expect Miracles Foundation
“The Board’s new Directors share a deep passion for our cause and proven leadership, which will be key to advancing the Foundation’s impact. Their commitment to creating both a better today and a brighter tomorrow for those impacted by cancer will be crucial to our mission—this year and beyond,” said Frank Heavey, Executive Director of Expect Miracles Foundation.
After such a successful 2021, The Foundation is delighted to continue making important strides in funding both innovative cancer research and critical support for young adult survivors. This ambitious and tenacious group of new Board members will be integral to the Foundation’s growth.
